Sign In
Buy FATE
$2.22
-0.350 (-13.62%)
At Close: Jun 03, 2026
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q1 2021 Results - Earnings Call Transcript
11:39pm, Wednesday, 05'th May 2021
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q1 2021 Results - Earnings Call Transcript
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
06:25pm, Wednesday, 05'th May 2021
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -14.29% and 57.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ARK Genomic Revolution ETF: Value Realization Will Take Time
04:46am, Monday, 03'rd May 2021
ARK Genomic Revolution ETF: Value Realization Will Take Time
Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting
04:31pm, Tuesday, 27'th Apr 2021
Two Oral Presentations to Cover iPSC-derived Cell-based Cancer Immunotherapy Pipeline
3 Hot Healthcare Stocks Cathie Wood Is Buying in April
06:01am, Saturday, 17'th Apr 2021
Here's why she likes them so much.
Immunocore: 'Off-The-Shelf' T Cell Therapy
11:13am, Monday, 12'th Apr 2021
Immunocore: 'Off-The-Shelf' T Cell Therapy
3 of the Most Innovative Stocks to Buy Now
06:20am, Friday, 02'nd Apr 2021
Here's how shares a diversified e-commerce firm, an immunotherapy biotech, and an electronic agreement company can make you rich.
Eli Casdin on looking for opportunity in life sciences
01:42pm, Thursday, 01'st Apr 2021
Eli Casdin, Casdin Capital founder and CIO, on the top life sciences opportunities he sees in the markets, and how he decides which companies are good investments.
Regenerative Medicine Attracted Record $20 Billion in Funding in 2020
02:15pm, Tuesday, 23'rd Mar 2021
Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.
7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines
11:54am, Friday, 12'th Mar 2021
If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Co
Fate Therapeutics to Present at Upcoming Investor Conferences
07:00am, Monday, 08'th Mar 2021
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the develo
FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses
01:40pm, Thursday, 25'th Feb 2021
FATE reports a wider Q4 loss on increased R&D expenses.
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2020 Results - Earnings Call Transcript
12:18am, Thursday, 25'th Feb 2021
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2020 Results - Earnings Call Transcript
Fate Therapeutics: Q4 Earnings Insights
04:55pm, Wednesday, 24'th Feb 2021
Shares of Fate Therapeutics (NASDAQ:FATE) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 64.86% over the past year to ($0.61), which
Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress
04:01pm, Wednesday, 24'th Feb 2021
Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3
